Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Globe Newswire

06:11 EST 25th November 2017 | BioPortfolio

Here are the most relevant search results for "Globe Newswire" found in our extensive news archives from over 250 global news sources.

More Information about Globe Newswire on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Globe Newswire for you to read. Along with our medical data and news we also list Globe Newswire Clinical Trials, which are updated daily. BioPortfolio also has a large database of Globe Newswire Companies for you to search.

Showing News Articles 1–25 of 49,000+ from Globe Newswire

Thursday 23rd November 2017

Cytori Announces Expiration of Oversubscribed Rights Offering

Rights Offering Oversubscribed by more than 75% SAN DIEGO, Nov. 24, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), announced today that the subscription period for its previously announced rights offering (the “Offering”) of units at a subscription price of $1,000 per unit expired on November 21, 2017, and these rights are no longer exercis...

Tuesday 21st November 2017

IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 15, 2017

BETHESDA, Md., Nov. 22, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), adjourned again the voting for Proposals Three and Four from its Notice of Annual Meeting of Shareholders, dated October 5, 2017.  Proposal Three seeks approval of the grant of 1,900,000 shares of common stock to be granted from time to time to the Company’s current and new employees, ad...

Cannevert Scientists to Present Their First Peer-Reviewed Research at December’s Prestigious British Pharmacological Society Meeting in London, UK

VANCOUVER, British Columbia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that the scientists of its research arm, Cannevert Therapeutics Ltd. ("CTL") will be presenting their first peer-reviewed research of its cannabis strains targeting pain at the British Pharmacological Meeting (BPS) in London, ...

Innate Pharma provides an update on Lirilumab

INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB Lirilumab continues to be well-tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb The combination of nivolumab plus lirilumab in an extended population of patients with squamous cell carcinoma of the head and neck (SCCHN) did not provid...

Axim Biotechnologies Reports Third Quarter 2017 Results

­­ NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter ended September 30, 2017, and provided an overview of recent operational highlights. “We are very excited to see clinical evidence of our theory and the therapeutic effects of CBD g...

Aquinox to Participate in 29th Annual Piper Jaffray Healthcare Conference

VANCOUVER, British Columbia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will participate in a fireside chat presentation at the upcoming 2...

Novan to Present at Piper Jaffray 29th Annual Healthcare Conference

MORRISVILLE, N.C., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Nathan Stasko, PhD, President and Chief Scientific Officer of Novan, is scheduled to participate in a fireside chat at the Piper Jaffray 29th Annual Healthcare Conference, Wednesday, Nov. 29, 2017, 12:00 p.m. EST, in New York. The presentation will be webcast live a...

Teligent, Inc. Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%

BUENA, N.J., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Hydrocortisone Butyrate Lotion 0.1%.  This is Teligent’s ninth approval for 2017, and its nineteenth a...

Vilacto Bio Inc. speeds up cooperation with Pharma GP to reach higher targets

COPENHAGEN, Denmark, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that within the next 3 month, the company will be taking over the online sales from Pharma GP direct to customers outside of the US. After having built its e commerce portal, www.vilacto.com, the company is ready to manage sales in higher volume and is targeting 8 figure annual sale...

Collegium to Present at the 29th Annual Piper Jaffray Healthcare Conference

CANTON, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that senior management will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference at 2:30pm ET on Tuesday, November 28, 2017 in New York City. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing...

Kalytera Announces $5 Million Private Placement of Convertible Debenture Units

/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) --  Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") announced today that it has entered into an agreement with Echelon Wealth Partners Inc. (“Echelon” or the "Agent"), to lead a brokered best efforts...

Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare Conference

BOTHELL, Wash., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the 29th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET on Wednesday, November 29, 2017 in New York. The presentation will feature a business...

Athenex to Present at 29th Annual Piper Jaffray Healthcare Conference

BUFFALO, N.Y., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Johnson Lau, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, N...

DiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase 2 Trial for Acute Ischemic Stroke

MINNEAPOLIS, Nov. 22, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), announced it has received ethics committee approval to initiate the first clinical site for its Phase 2 REMEDY clinical trial with DM199 (recombinant human KLK1). REMEDY is a multi-center, double-blind, randomized, placebo-controlled Phase 2 clinical trial investig...

Summit Therapeutics to Participate in Upcoming Investor Conferences

OXFORD, United Kingdom, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that management will participate in two upcoming investor conferences in New York City, US. 29th Annual Piper Jaffray Healthcare Co...

Evogene Reports Third Quarter 2017 Financial Results

REHOVOT, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today its financial results for the third quarter ending September 30, 2017. Ofer Haviv, Evogene's President and CEO, stated: “This is a...

Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study

Patent relates to the use of Mesenchymal Stem Cells (MSCs) for muscle regeneration following muscle injuryPivotal Phase III study to take place in U.S. and Europe to support recovery from hip fracture HAIFA, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S...

Avivagen Announces the Appointment of Mr. Aubrey Dan to the Board of Directors

OTTAWA, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health,  is delighted to welcome Mr. Aubrey Dan to the Board of Directors. Mr. Dan is a Canadian businessman, philanthropist and Tony-Award® winning theatr...

Monday 20th November 2017

Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the Company’s Prior Approval Supplement (PAS) for Bevyxxa® (betrixaban) to allow the agency time to review the entire submission. The FDA informed the Company today that it will resp...

Prima Secures European Patent Grant for Lead Product IMP321 in Cancer

SYDNEY, Australia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of patent number 2604275 entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the European Patent Office. This European patent was filed as a divisional application and follows the grant...

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Patrick Jeanmart, Chief Financial Officer and David Gilham, VP Research and Development of Celyad will present a corporate update at the upcoming 29th Annual Piper Jaffray H...

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference

ROCKVILLE, Md., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th at 11:30AM Eastern. Investors interested in arranging a meeting with the Company's management during this confe...

Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference

AUSTIN, Texas, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, w...

Ascendis Pharma A/S Announces Participation in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

COPENHAGEN, Denmark, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upcoming investor conference. Jan Mikkelsen, President and CEO, and Scott T. Smith, Senior Vice President and...

480 Biomedical’s Novel Technology Featured in Nature Materials

WATERTOWN, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- 480 Biomedical, a clinical-stage life science company committed to transforming the lives of patients with chronic diseases, announced a publication in Nature Materials highlighting the novel mechanical properties of the company’s fully bioresorbable polymeric implant technology. As described in Nature Materials, the 480 Biomedical impl...


Quick Search
Advertisement
 

News Quicklinks